nav-left cat-right
cat-right

Antibody Drug Conjugates Conference October 22-23,...

We invite you to attend the Antibody Drug Conjugates Conference, which will take place October 22-23, 2015 in Boston, MA. This event will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain a fresh perspective on the emergence of recent data from ADC clinical trials, new linkers and payloads, personalized...

2nd Bioinformatics & Drug Discovery Conferenc...

We are pleased to invite you to the 2nd Bioinformatics & Drug Discovery Conference, which will take place October 5-6, 2015 in Berlin, Germany. The conference will bring together the world’s leading bioinformaticians and discuss developments in NGS big data, cloud systems, clinical and cancer genomics data, and database integration. This conference is part our larger Technologies in Drug Discovery Summit Europe which...

Technologies in Drug Discovery Summit Europe Octob...

We are pleased to invite you to the Technologies in Drug Discovery Summit Europe, which will take place October 5-8, 2015 in Berlin, Germany. The summit will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain fresh perspective on the various research happening. Technologies in Drug Discovery Summit Europe will...

Companion Diagnostics Conference June 11-12, 2015,...

GTCbio invite you to the Companion Diagnostics Conference, which takes place June 11-12, 2015 in San Diego, CA at the Hyatt Regency Mission Bay. CDx play a significant role in the area of personalized medicine for viral diseases and drug development. There are opportunities and limitations in companion diagnostics and its combination with next generation sequencing towards targeted therapeutic areas. Join fellow researchers...

XL-protein Signs Licensing Agreement with MSD Anim...

FREISING, GERMANY, February 12, 2015 – XL-protein GmbH, Germany, a privately owned biopharmaceutical company, announced today that they have entered into a license agreement with MSD Animal Health (known as Merck Animal Health in the USA and Canada) to develop PASylated biopharmaceuticals for use in animal health. This license agreement follows a research collaboration between the two companies which began in 2012 and...

Zedira receives further funding to develop Factor ...

Zedira has received further funding from the German Federal Ministry for Education and Research (German abbreviation: BMBF). The project volume has been extended by € 1.0 Mio. so that the total project value exceeds € 5.0 Mio. by now. The additional funding will allow completing the development of a drug candidate for „safe“ anticoagulation. Zedira targets coagulation factor XIIIa (F13, plasma transglutaminase) using...
Page 3 of 3412345...102030...Last »